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feBackground: Chronic spontaneous urticaria is characterized by recurrent itchy wheals. First-line
management is with H1-antihistamines.Objective: We sought to conduct a Cochrane Review of H1-antihistamines in the treatment of chronic
spontaneous urticaria.Methods: A systematic search of major databases for randomized controlled trials was conducted.Results: We included 73 studies with 9759 participants; 34 studies provided outcome data for 23
comparisons. Compared with placebo, cetirizine 10 mg daily in the short and intermediate term (RR 2.72;
95% confidence interval [CI] 1.51-4.91) led to complete suppression of urticaria. Levocetirizine 20 mg daily
was effective for short-term use (RR 20.87; 95% CI 1.37-317.60) as was 5 mg for intermediate-term use (RR
52.88; 95% CI 3.31-843.81). Desloratadine 20 mg was effective for the short term (RR 15.97; 95% CI 1.04-
245.04) as was 5 mg in the intermediate term (RR 37.00; 95% CI 2.31-593.70). There was no evidence to
suggest difference in adverse event rates between treatments.Limitations: Some methodological limitations were observed. Few studies for each comparison reported
outcome data that could be incorporated in meta-analyses.Conclusions: At standard doses, several antihistamines are effective and safe in complete suppression of
chronic spontaneous urticaria. Research on long-term treatment using standardized outcome measures and
quality of life scores is needed. ( J Am Acad Dermatol http://dx.doi.org/10.1016/j.jaad.2015.06.048.)
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2 Sharma et alChronic spontaneous urticaria (CSU), previously
known as chronic idiopathic urticaria or chronic
ordinary urticaria, is characterized by recurrent itchy
wheals that appear for no identifiable reason. The
condition is termed ‘‘chronic’’ when recurrent crops
appear for more than 6 weeks.1 There is a female to
male predominance of 2:12 with a prevalence ofCAPSULE SUMMARY
d Chronic spontaneous urticaria is
characterized by recurrent itchy wheals.
First-line treatment is with H1-
antihistamines.
d At standard doses, several antihistamines
are effective and safe compared with
placebo. Evidence for higher dosing is
scarce.
d Further research is needed for longer
duration of treatment using
standardized and validated scores.between 0.5% and 1%.3 The
lack of predictability and fre-
quency of symptoms often
leads to distress and anxiety.
H1-antihistamines are the
mainstay of treatment. These
are usually classified as
first- or second-generation
according to their chemical
structure and properties.
Second-generation antihis-
tamines tend to be less
sedating.4
METHODS
Inclusion criteria
We included randomized
controlled trials that evaluated the effectiveness
of H1-antihistamines compared with placebo or
another active treatment. Individuals of any age
with a clinical diagnosis of CSU, chronic idiopathic
urticaria, or chronic ordinary urticaria and use of
H1-antihistamines at any dose, including topical
interventions, were included. Terfenadine and
astemizole were not included as they have been
withdrawn from international markets because of
safety issues. The interventions could be either
single or combination therapy. The duration of
intervention was categorized as short term (up to
2 weeks), more than 2 weeks to 3 months (inter-
mediate term), and more than 3 months (long
term).
Data extraction
Three authors extracted data independently using
a data extraction form; any disagreements were
resolved by consensus.
Searches
We searched the following databases up to June
2014: Cochrane Skin Group Specialised Register,
CENTRAL (2014, Issue 5), MEDLINE (from 1946),
EMBASE (from 1974), and PsycINFO (from 1806).We
searched 5 trials registers and checked articles for
references to relevant randomized controlled trials.
We contacted principal investigators for missing
data.REV 5.2.0 DTD  YMJD10352_prOutcomes
We extracted data from studies based on 3 primary
outcomes agreed on in the protocol of the review.
These were the proportion of participants with
complete suppression of urticaria, the proportion
with good or excellent response while taking
H1-antihistamines, and the proportion with 50%oof  30 July 2015  6:31 por greater improvement in
quality of life (QoL) mea-
sures while taking H1-
antihistamines.
We extracted data on 3
secondary outcomes: serious
adverse events (requiring
withdrawal of treatment),
minor participant-reported
adverse events not requiring
withdrawal of treatment, and
the proportion of partici-
pants who relapse within
1 month of stopping H1-
antihistamines.
Review authors checked
and entered the outcomedata (numeric and nonnumeric) into RevMan data
analysis software.5 We used the Cochrane
Collaboration’s tool for assessing risk of bias, and
rated the Cochrane risk of bias domains for each
included study as low risk of bias, high risk of bias,
and unclear if the risk of bias was uncertain or
unknown.5 We reported data according to a treat-
ment by allocation principle whenever possible,
and according to section 16.2.2 of the Cochrane
Handbook for Systematic Reviews of Interventions.6
If authors only presented a per-protocol analysis
we assessed dropout imbalance between the trial
arms. In the absence of intention-to-treat data, we
used available case population data (per protocol)
and reported this accordingly. We have presented
continuous outcomes with a change from baseline
or standardized mean difference and dichotomous
outcomes as risk ratios (RR) with 95% confidence
intervals (CI). Where we identified clinically
similar studies that exhibited no worse than mod-
erate heterogeneity (I2 \ 60%), we pooled the
data into a meta-analysis using a Mantel-Haenszel
or inverse-variance (dichotomous or continuous
data, respectively) method with a random effects
model. We conducted subgroup analyses based
on the duration of the intervention.
RESULTS
We identified 1080 references from our electronic
database searches up to June 2014. In total, 73 studies
(82 records) were included in the qualitative analysism
[F2-4/C]
Abbreviations used:
CI: confidence interval
CSU: chronic spontaneous urticaria
QoL: quality of life
RR: risk ratio
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Sharma et al 3(Fig 1). Of the 73 included studies, 34 yielded data for
23 comparisons (online supplementary material
available at http://www.jaad.org).
The total number of randomized participants was
9759 comprising adults or mixed groups including
adolescents (ie, [12 years old) and was predomi-
nantly female.
Interventions
The comparisons included first- and second-
generation antihistamines; montelukast, a leuko-
triene receptor antagonist7; and doxepin, a sedative
tricyclic antidepressant.8
Seventeen studies included a short-term duration
of intervention9-25 and the duration of intervention
was not explicitly stated in 1 study26 but we
categorized this as short term on the basis of infor-
mation given in the abstract report. One study27 was
of very short duration (5 hours) and the remaining 55
studies were intermediate-term duration. No studies
had a long-term duration ([3 months). Sample sizes
varied from several hundred participants to fewer
than 25.
No study provided complete clarity on every item
in our risk of bias assessment. Of the 73 included
studies, 37 (50%) had at least 1 element of selection
bias, performance and detection bias, attrition bias,
or reporting bias that we rated as at high risk of bias
(Fig 2). Other issues that could suggest a high risk of
bias (eg, potential conflicts of interest, pharmaceu-
tical funding or support) were also assessed. There
were some notable methodological limitations in the
included studies. Only 12 studies demonstrated clear
and adequate randomization methods, and only 5
had adequate allocation concealment. Blinding of
participants and personnel was adequate in 22
studies and blinding of outcome assessors adequate
in 14. In 20 studies, the distribution or high number
of dropouts or losses to follow-up could have
introduced bias. In all, 24 studies were judged to
be at low risk for selective reporting. A total of 19
studies for which no funding or sponsorship was
declared were assessed as having low risk of bias, as
we detected no other bias.
Studies on cetirizine (10 mg daily)
Four studies compared cetirizine 10 mg versus
placebo.10,28-30 There was clear evidence thatREV 5.2.0 DTD  YMJD10352_prcetirizine increased the cessation of urticaria (RR
2.72; 95% CI 1.51-4.91; P \ .001; I2 = 0%). One
study28 reported an increase in good response after
treatment was seen in 45 of 60 (cetirizine) and 29 of
62 (placebo) participants (P = .001). Seven partici-
pants in 3 studies28-30 withdrew because of adverse
events, and 2 while taking placebo, that suggested a
possible increase caused by cetirizine over the
intermediate term; however, this was not statistically
significant (RR 3.00; 95% CI 0.68-13.22; P = .15;
I2 = 0%). Two studies21,31 compared cetirizine 10 mg
versus loratadine 10 mg. Both reported a similar
proportion of participants with complete suppres-
sion of urticaria in each group. Overall, combining
data from both studies, the RR was 1.05 (95% CI
0.76-1.43; P = .77; I2 = 0%) indicating no evidence of
a difference. Two studies were identified that
compared cetirizine 10 mg versus hydroxyzine
25 mg.29,30 Both studies reported the number of
participants who withdrew because of an adverse
event with no evidence of a difference (RR of
withdrawal 0.78; 95% CI 0.25-2.45; P = .67;
I2 = 0%). One study compared cetirizine 10 mg
versus fexofenadine 180 mg32 and found that cetir-
izine increased the suppression of urticaria: 27 of 59
(cetirizine) compared with 2 of 57 (fexofenadine)
(P \ .001). One study compared cetirizine 10 mg
versus levocetirizine 5 mg33 and reported no differ-
ence in the suppression of urticaria or response to
treatment. One study compared cetirizine 10 mg
versus mizolastine 10 mg31 and reported no differ-
ence in the complete suppression of urticaria or at
least good response to treatment (P = .60).
Studies on desloratadine (5-20 mg daily)
Six studies compared desloratadine 5 to 20 mg
versus placebo.7,26,34-37 One did not provide efficacy
data that could be included in our meta-analyses.36
Another26 investigated 3 doses of desloratadine (5,
10, and 20mg) compared with placebo using a short-
term duration of intervention and reported suppres-
sion of urticaria in 4 of 34, 11 of 34, 21 of 34, and 0 of
36 participants, respectively, suggesting a dose-
response relationship. One study34 used an interme-
diate term of intervention and reported complete
suppression of urticaria in 18 of 40 (desloratadine
5 mg) and 0 of 40 (placebo) (P\ .001). We did not
pool across all dosages and durations of interven-
tion, but because no participants in the placebo
group exhibited suppression of urticaria, a Fishers
Exact test was used to compare the two (53 of 142
desloratadine and 0 of 76 placebo). The 95% CI for
the OR was between 7.12 and infinity (P \ .001).
Additional data obtained from the principal investi-
gator of the study by Di Lorenzo et al7 in 2004oof  30 July 2015  6:31 pm
Fig 1. PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) diagram
of study flow.
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0 of 40 participants in the placebo group experi-
enced an excellent response (P\ .001). In all, 34 of
49 participants (desloratadine 5 mg) and 23 of 36
(placebo) exhibited an improvement in QoL.36 There
was no significant difference in withdrawals as a
result of adverse effects between desloratadine 5 mg
and placebo (RR 1.46; CI 0.42-5.1).35,37 Two studies
compared levocetirizine 5 to 20 mg with deslorata-
dine 5 to 20 mg.26,38 No meta-analysis was possible
for this comparison. The proportion of participants
exhibiting suppression of urticaria in the deslorata-
dine group (5, 10, and 20 mg) was 4, 11, and 21 of 34.
The higher dose results in this small study might
suggest that higher doses were more effective. The
second study38 found an increased chance of a goodREV 5.2.0 DTD  YMJD10352_prtreatment response from levocetirizine 5 mg
compared with desloratadine 5 mg (294 of 438 vs
256 of 448). Levocetirizine appeared to be more
effective than desloratadine. In an intermediate-term
duration of intervention study,39 levocetirizine
completely suppressed urticaria in 27 of 51 partici-
pants compared with placebo (0 of 51) (P\.001). In
neither study were there withdrawals because of
adverse effects. One study compared desloratadine
5 mg versus montelukast 10 mg.7 There was an
increase in complete suppression and response in
the desloratadine group (P = .008 and P \ .001,
respectively). Adverse events were noted to be of
low frequency, but a large number of withdrawals
occurred because of lack of efficacy in the group not
receiving desloratadine.oof  30 July 2015  6:31 pm
Fig 2. Graph of bias risk.
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Sharma et al 5Three studies40-42 with a total of 410 participants
reported no significant difference in efficacy be-
tween loratadine 10 mg and desloratadine 5 mg (RR
1.04; CI 0.64-1.71). In 2 of these41,42 with medications
taken once daily over an intermediate-term duration,
the RR for complete suppression of disease was 0.91
(CI 0.78-1.06; P = .22; I2 = 0%). All 3 studies
individually concluded that loratadine and deslor-
atadine were safe and effective for CSU. No pooling
of adverse events was carried out, but the main side
effects reported included mouth dryness, dizziness,
and headache.
Studies on loratadine (10 mg daily)
Two studies compared loratadine 10 mg and
placebo.20 A combined analysis suggested that
loratadine may increase the chance of a participant
experiencing a good response, expressed as a risk
ratio (RR) of 1.86 (95% CI 0.91-3.79; P = .09; I2 = 0%).
Four studies were identified that compared lor-
atadine 10 mg versus mizolastine 10 mg.18,31,43,44
Three of these assessed complete suppression of
urticaria and a good response but a difference
between treatments was found for neither outcome
(RR 0.86; CI 0.64-1.16; I2 = 55%; P = .109; and RR 0.9;
CI 0.56-1.43; P = .64; I2 = 0%, respectively). Two of
these studies43,44 reported an improvement in QoL of
at least 50% but without significant difference be-
tween the treatments (RR 3.21; CI 0.32-32.33;
I2 = 65%). There was no difference in numbers of
withdrawals as a result of adverse events (RR 0.38; CI
0.04-3.6; P = .40; I2 = 0%). A single study of loratadine
10 mg versus emedastine 2 mg45 reported no differ-
ence in suppression of urticaria or response to
treatment (RR 1.04; 95% CI 0.78-1.39; good response
RR 1.09; 95% CI 0.96-1.24). No withdrawals attribut-
able to the study medications occurred. Comparison
of loratadine versus desloratadine is detailed above.
One study compared loratadine 10 mg versus
hydroxyzine 25 mg20 and found no difference in the
suppression of urticaria (RR 1.00; 95% CI 0.32-3.10).REV 5.2.0 DTD  YMJD10352_prOverall, 8 of 20 participants in the hydroxyzine
group and 1 of 20 in the loratadine group reported
sedation as a minor adverse event (P = .02).
Studies on hydroxyzine (25 mg daily)
Three studies were identified that compared hy-
droxyzine 25 mg versus placebo.20,29,30 However,
the small number of participants in each meant little
evidence of any difference between the interven-
tions in terms of efficacy. For adverse events there
was similarly little evidence of differences between
interventions.29,30 One study mentioned above as-
sessed hydroxyzine versus loratadine.
Studies on rupatadine (10-20 mg daily)
One study compared rupatadine 10 to 20 mg
versus placebo over an intermediate-term duration
of intervention (n = 122).46 Meta-analysis of the
pooled RR between rupatadine (at both doses) and
placebo was 1.35 (95% CI 1.03-1.77; P = .03; I2 = 0%);
thus, rupatadine increased the chance of a good
response but there was little evidence to indicate that
10 mg was more effective than 20 mg.
Other comparisons
One study22 compared ebastine 10 mg versus
placebo and found no statistically significant differ-
ence in efficacy (Fisher exact test P = .13).
Another compared fexofenadine 180 mg versus
placebo.47 Although no significant differences were
found in suppression of urticaria (P = .272), at least a
good response was more frequent with fexofena-
dine: 57 of 162 (fexofenadine) and 11 of 91 (placebo)
(P\ .001). Participants who were previously unre-
sponsive to antihistamines were excluded, so this
result may not be generalizable.
For ketotifen 1 mg (with chlorpheniramine 4 mg
as required) versus placebo,23 the requirement for
chlorpheniramine dropped in significantly more
participants taking ketotifen than placebo (94% vs
7%). For doxepin 10mg versus pheniramine 22.5mg,oof  30 July 2015  6:31 pm
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6 Sharma et al8 of 28 and 3 of 28 participants experienced
complete suppression of urticaria (doxepin and
pheniramine, respectively; P\ .001). A small study
of azelastine 2 mg versus azelastine 4 mg48 found no
efficacy differences. For further details of these
analyses, please see the full review within the
Cochrane Library.49
DISCUSSION
The evidence indicates that several antihistamines
are effective in suppressing CSU. The primary studies
included in this review individually carry a varying risk
of bias (Fig 2). For general use, to achieve complete
suppression of urticaria, the evidence supports the use
of cetirizine at 10 mg once daily for short- and
intermediate-term duration. There may be benefit in
using desloratadine at 5 mg once daily for at least an
intermediate term of intervention and 20 mg deslor-
atadine in the short term. Levocetirizine at 5 mg once
daily in the intermediate term also appears to be
effective at achieving complete suppression of CSU.
This is basedon the results of 3 trials.We rated2of these
as carrying an unclear risk of bias in every domain,
although the third study, while small, was relatively
well conducted and reported. Although we included
trials of various other drugs, the data are too sparse to
draw firm conclusions about their relative efficacy.
There is some evidence to support the use of
higher doses of antihistamines (eg, levocetirizine up
to 20 mg) as recommended in the European guide-
lines50 and future work should address these gaps.
Few of the included studies reported data that
corresponded with the predetermined outcomes of
this review. Primary outcome scores were variable,
making direct comparisons difficult. We have drawn
limited conclusions from single-study analyses, re-
ported trial results narratively, or presented results
from small meta-analyses of up to 3 studies. Overall
there was mixed evidence and each comparison was
rated as moderate or low quality.
CSU can last for several years. We found no
studies lasting over 3 months. Only 9 trials assessed
whether responses were sustained after stopping
the intervention. Trials with active treatment
arms rather than a placebo, with comparisons of
different doses over longer periods would be a more
comprehensive way to gather relevant information.
In future research, we would favor the use of
standardized outcome scores such as the Urticaria
Activity Score 7, which comprises the daily sum of
4-point scales (0-3) for number of wheals and pru-
ritus over 7 days and is recommended in the
European guidelines.50 This, along with validated
QoL scores for trial participants, would provide
comparable data to help aid treatment decisions.REV 5.2.0 DTD  YMJD10352_prThe authors acknowledge Dr Gudula Kirtschig and the
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Review.S1COMPARISONS USED IN ANALYSES
A total of 73 trials met our inclusion criteria. Of
these, only 34 trials provided outcome data for the
following comparisons.S2-S72
d Loratadine 10 mg versus placebo (Belaich et al,S2
1990; Monroe,S3 1992).
d Loratadine 10 mg versus cetirizine 10 mg (Patel
and Danzig,S4 1997; Yin et al,S5 2003).
d Loratadine 10 mg versus desloratadine 5 mg (Gu
et al,S6 2002; Hao et al,S7 2003; Zou and Chen,S8
2002).
d Loratadine 10 mg versus mizolastine 10 mg (Guo
et al,S9 2003; Leynadier et al,S10 2000; Liu et al,S11
2003; Yin et al,S5 2003).
d Loratadine 10 mg versus emedastine 2 mg (Pons-
Guiraud et al,S12 2006).
d Loratadine 10 mg versus hydroxyzine 25 mg
(Monroe,S3 1992).
d Cetirizine 10 mg versus placebo (Breneman
et al,S13 1995; Breneman,S14 1996; Go et al,S15
1989; Kalivas et al,S16 1990).
d Cetirizine 10 mg versus hydroxyzine 25 mg (Bre-
neman,S14 1996; Kalivas et al,S16 1990).
d Cetirizine 10 mg versus fexofenadine 180 mg
(Handa et al,S17 2004).
d Cetirizine 10 mg versus levocetirizine 5 mg (Yin
et al,S18 2003).
d Cetirizine 10 mg versus mizolastine 10 mg (Yin
et al,S5 2003).
d Desloratadine 5 mg to 20 mg versus placebo (Di
Lorenzo et al,S19 2004; Hoxha et al,S20 2011;
Monroe et al,S21 2003; Nettis et al,S22 2004; Or-
tonne et al,S23 2007; Ring et al,S24 2001).
d Hydroxyzine 25 mg versus placebo (Breneman,S14
1996; Kalivas et al,S16 1990; Monroe,S3 1992).
d Levocetirizine 5 mg to 20 mg versus placebo
(Hoxha et al,S20 2011; Nettis,S72 2006).
d Rupatadine 10 mg to 20 mg versus placebo
(Gimenez-Arnau et al,S25 2007).
d Desloratadine 5 mg to 20 mg versus levocetirizine
5 to 20 mg (Hoxha et al,S20 2011; Potter et al,S26
2009).
d Ebastine 10 mg versus placebo (Peyri et al,S27
1991).
d Desloratadine 5 mg versus montelukast 10 mg (Di
Lorenzo et al,S19 2004).
d Fexofenadine 180 mg versus placebo (Kaplan
et al,S28 2005).
d Ketotifen 1 mg versus placebo (Phanuphak
et al,S29 1987).REV 5.2.0 DTD  YMJD10352_prd Cetirizine 5 mg and hydroxyzine 25 mg versus
placebo (Wan,S30 2009).
d Azelastine 2 mg versus azelastine 4 mg (Wu
et al,S31 2008).
d Doxepin 10 mg versus pheniramine 22.5 mg
(Ghosh and Haldar,S32 1990).
A number of studies compared interventions that
could not be included in our analyses because the
outcomes measured did not fit our inclusion criteria.
d Acrivastine 4 mg, placebo, clemastine 1 mg (Ley-
nadier et al,S10 2000).
d Acrivastine 8 mg, chlorphen(ir)amine maleate
4 mg (Gale et al,S33 1989).
d Acrivastine 8 mg, clemastine 1 mg, placebo
(Juhlin et al,S34 1987).
d Acrivastine 8 mg, hydroxyzine hydrochloride
20 mg (Salo et al,S35 1989).
d Azelastine 2 mg, azelastine 4 mg, azelastine
and cimetidine (histamine H2-receptor antagonist
[H2RA]) 2 mg (Wu et al,S31 2008).
d Cetirizine 10 mg, placebo (Juhlin,S36 1991).
d Cetirizine 10 mg plus placebo, terfenadine 60 mg,
placebo (Go et al,S15 1989; Kint et al,S37 1989).
d Cetirizine 10 mg, terfenadine 120 mg, placebo
(Garavaglia et al,S38 1995).
d Cetirizine 10mg, placebo (cross-over) (Goh et al,S39
1991); non-cross-over (Alomar et al,S40 1990).
d Cetirizine 10 mg versus rupatadine 10 mg (Da-
khale et al,S41 2014).
d Chlorphen(ir)amine 4 mg, chlorphen(ir)amine
4 mg plus cimetidine 400 mg (H1 1 H2 antago-
nist), placebo (Marks,S42 1980).
d Cimetidine 200 mg plus chlorphen(ir)amine 4 mg,
chlorphen(ir)amine 4 mg plus placebo, placebo
(Commens and Greaves,S43 1978).
d Desloratadine 5 mg, placebo (Bronsky,S44 2001;
Monroe et al,S21 2003; Ortonne et al,S45 2004;
Ortonne et al,S23 2007; Ring et al,S24 2001).
d Desloratadine 5 mg, desloratadine 10 mg, deslor-
atadine 20 mg (NCT00536380S46).
d Desloratadine 5 mg, desloratadine 20 mg (Weller
et al,S47 2013).
d Desloratadine 5 mg and placebo, desloratadine
5 mg and montelukast 10 mg, placebo (Nettis
et al,S22 2004).
d Fexofenadine 60, 120, 180, and 240 mg; placebo
(Paul et al,S48 1998).
d Fexofenadine 60 mg, placebo (Thompson et al,S49
2000).
d Fexofenadine hydrochloride (HCl) 180 mg, levo-
cetirizine 5 mg (Godse et al,S50 2007).
d Fexofenadine HCl 20, 60, 120, and 240 mg; pla-
cebo (Finn et al,S51 1999; Nelson et al,S52 2000).
d Fexofenadine 180 mg, placebo (Degonda et al,S53
2002).oof  30 July 2015  6:31 pm
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loratadine and cetirizine in patients with chronic idiopathic
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S5. Yin R, Diao QC, Ye QY. Clinical research of three antihista-
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Dermatol (Nanjing). 2003;32:675-677.
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S8. Zou Y, Chen XP. Curative effect of desloratadine in the
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research of mizolastine for the treatment of idiopathic
chronic urticaria. West China Med J. 2003;18:482-483.
S10. Leynadier F, Duarte-Risselin C, Murrieta M. Comparative
therapeutic effect and safety of mizolastine and loratadine
in chronic idiopathic urticaria. URTILOR study group. Eur J
Dermatol. 2000;10:205-211.
S11. Liu LL, Zhu XJ, Jiang W, et al. A multicenter, double-blind,
randomized, parallel comparative study on the efficacy
and safety of mizolastine versus loratadine in the treat-
ment of chronic urticaria. Chinese J Dermatol. 2003;36:
306-309.
S12. Pons-Guiraud A, Nekam K, Lahovsky J, et al. Emedastine
difumarate versus loratadine in chronic idiopathic urticaria: a
randomized, double-blind, controlled European multicenter
clinical trial. Eur J Dermatol. 2006;16:649-654.
S13. Breneman D, Bronsky EA, Bruce S, et al. Cetirizine and
astemizole therapy for chronic idiopathic urticaria: a
double-blind, placebo-controlled, comparative trial. J Am
Acad Dermatol. 1995;33(2 Pt 1):192-198.
S14. Breneman DL. Cetirizine versus hydroxyzine and placebo in
chronic idiopathic urticaria. Ann Pharmacother. 1996;30:
1075-1079.
S15. Go M, Wuite J, Arendt C, et al. Double-blind, placebo
controlled comparison of cetirizine and terfenadine in
chronic idiopathic urticaria. Acta Therap. 1989;15:77-86.
S16. Kalivas J, Breneman D, Tharp M, et al. Urticaria: clinical
efficacy of cetirizine in comparison with hydroxyzine and
placebo. J Allergy Clin Immunol. 1990;86:1014-1018.
S17. Handa S, Dogra S, Kumar B. Comparative efficacy of cetirizine
and fexofenadine in the treatment of chronic idiopathic
urticaria. J Dermatolog Treat. 2004;15:55-57.
S18. Yin R, Hao F, Xiang MM, et al. A clinical trial of levocetirizine
in the treatment of chronic idiopathic urticaria. J Clin
Dermatol (Nanjing). 2003;32:477-478.
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Sharma et al 7.e2d Hydroxyzine plus terbutaline (beta agonist) (25 mg
plus 5 mg), hydroxyzine plus cyproheptadine
(25 mg plus 4 mg), hydroxyzine plus chlorphe-
n(ir)amine (25 mg plus 4 mg), hydroxyzine plus
cimetidine (H2RA) (25 mg plus 300 mg), hydroxy-
zine plus placebo (25 mg) (Harvey et al,S54 1981).
d Ketotifen 1 mg, fluoxetine 20 mg (selective sero-
tonin reuptake inhibitoretype antidepressant)
(Sener et al,S55 1999).
d Levocetirizine 5 mg, bilastine 20 mg (Zuberbier
et al,S56 2010).
d Levocetirizine 5 mg, desloratadine 5 mg (Potter
et al,S26 2009).
d Levocetirizine 20 mg, levocetirizine 15 mg plus
hydroxyzine 50 mg (Staevska et al,S57 2014).
d Loratadine 10 mg, levocetirizine 5 mg (Anuradha
et al,S58 2010).
d Loratadine 10 mg, placebo (Monroe et al,S59
1988).
d Mizolastine 10 mg, loratadine 10 mg, placebo
(Dubertret et al,S60 1999).
d Mizolastine 10 mg, placebo (Brostoff et al,S61
1996; Ollert et al,S62 1999).
d Mizolastine 10 mg in decreasing dose, mizolastine
10 mg daily (Wang et al,S63 2012).
d Nifedipine 10 mg, chlorphen(ir)amine 4 mg (Liu
et al,S64 1990).
d Olopatadine 10 mg, olopatadine 5 mg, no medi-
cation (Makino et al,S65 2012).
d Oxatomide 30 mg, clemastine 1 mg (Beck et al,S66
1985).
d Oxatomide gel 5%, dechlorpheniramine cream
(Locci and Del Giacco,S67 1991).
d Rupatadine 10 mg, levocetirizine 5 mg (Maiti
et al,S68 2011).
d Rupatadine 10 mg, rupatadine 20 mg, placebo
(Gimenez-Arnau et al,S25 2007).
d Rupatadine 5 mg, rupatadine 10 mg, rupatadine
20 mg, placebo (Dubertret et al,S69 2007).
d Terfenadine 60 mg, clemastine 1 mg, placebo
(Hjorth,S70 1988).
d Terfenadine 60 mg, chlorphen(ir)amine 4 mg,
placebo (Grant et al,S71 1988).REFERENCES
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